EN | TR
E-ISSN: 2149-6447
Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT
PDF
Cite
Share
Request
Guideline
VOLUME: 6 ISSUE: 3
P: 370-384
November 2020

Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT

Nucl Med Semin 2020;6(3):370-384
DOI: 10.4274/nts.galenos.2020.0030
Gülin Uçmak 1
İlknur Ak Sivrikoz 2
Nalan Alan Selçuk 3
Emre Demirci 3
Umut Elboğa 4
Cüneyt Türkmen 5
Levent Kabasakal 6
1. Sağlık Bilimleri Üniversitesi, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye
2. Osmangazi Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Eskişehir, Türkiye
3. Yeditepe Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
4. Gaziantep Üniversitesi, Şahinbey Araştırma ve Uygulama Hastanesi, Nükleer Tıp Anabilim Dalı, Gaziantep, Türkiye
5. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
6. İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Gallium-68 prostate specific membrane antigen (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) imaging in prostate cancer (PC). It is thought that guideline recommendations, in which the current scientific place of Ga-68 PSMA PET/CT and developing indications are also discussed, will contribute to increase the accuracy and reliability of Ga-68 PSMA imaging in PC.

References

1Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017;44:1014-1024. 
2Mottet N, Bellmunt J, Briers E. et al. Members of the EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Amsterdam 2020. 978-94-92671-07-3. Arnhem: EAU Guidelines Office; 2020.
3Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol 2020;38:1963-1996.
4Ministry of Health, Public Health, General Directorate of Turkey Cancer Statistics 2015; Ankara, 2018. Available from: hsgm.saglik.gov.tr.
5Siegel RL, Sahar L, Portier KM, et al. Cancer death rates in US congressional districts. CA Cancer J Clin 2015;65:339-344.
6Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989;39:376-393.
7Gleason DF. Classification of prostate carcinoma. Cancer Chemother Rep 1966;50:125-128.
8Gleason DF. Veterans Adminstration Cooperative Urological Research Group. 1977. Histologica grading and clinical staging of prostatic carcinoma. In: Urologic pathology: The prostate. editors Tannenbaum M: Lea & Febinger; Philadelphia. pp. 171-197.
9Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of grading paterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244-252.
10Moch H, Humphrey PA, Ulbright TM, Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer; 2016.
11Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
12Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997;49(Suppl 3A):104-112.
13Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
14Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (psma) on biopsies ıs an ındependent risk stratifier of prostate cancer patients at time of ınitial diagnosis. Front Oncol 2018;8:623.
15Bravaccini S. Puccetti M, Bocchini M, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
16Banerjee SR, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010;53:5333-5341.
17Eder M, Schafer M, Bauder-Wust U, et al. 68Ga -complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688-697.
18Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med 2015;56:1697-1705. 
19Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 2015;56:855-861.
20National Comprehensive Cancer Network. NCCN Clinical Guidelines in Oncology. Prostate Cancer. Version 2.2020. 2020; https://www.nccn.org/professionals/physician_gls/ pdf/prostate.pdf
21Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis Eur Urol 2019;77:403-417.
22Radwan N, Phillips R, Ross A, et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). BMC Cancer 2017;17:453.
23Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-453. Published 2017, Jun 29.
24Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531-547.
25Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014;2:273-285.
26Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (68)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
27Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015;42:1284-1294.
28Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209.
29Morigi JJ, Stricker PD, vanLeeuwen PJ, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients Who have rising PSA after curative treatment and Are being considered for targeted therapy. J Nucl Med 2015;56:1185-1190.
30Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relationto PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016;43:397-403.
31Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.  JAMA Oncol 2019;5:856-863.
32Calais J, Fendler WP, Eiber M, et al. Impact of 68Ga-PSMA-11PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 2018;59:434-441. 
33Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study.J Nucl Med 2020;61:1153-1160.
34Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment Outcomes from (68)Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med 2017;58:1972-1976.
35Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. [published correction appears in BMC Cancer 2019;19:97 Published 2019 Jan 7.
36Farolfi A, Gafita A, Calais J, et al. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol 2019;202:1174-1181.
37Deandreis D, Guarneri A, Ceci F, et al. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy.  [published online ahead of print, 2020 Apr 20]. Eur J Nucl Med Mol Imaging 2020;10.1007/s00259-020-04809-8.
38Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: aprospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446-453.
39Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21121.  
40Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68) gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016;195:1436-1443.
41Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/ computerized tomography. Prostate 2015;75:1934-1940.
42Ferraro DA, Muehlematter UJ, Garcia Schüler HI, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2020;47:147-159.
43Öbek C, Doğanca T, Demirci E, et al. Members of Urooncology Association, Turkey. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:1806-1812.
44Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book 2019;39:321-330.
45Calais J, Kishan AU, Cao M, et al. Potential Impact of Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 2018;59:1714-1721.
46Schiller K, Devecka M, Maurer T, et al. Impact of Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology-a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018;13:36. https://doi.org/10.1186/s13014-018-0977-2.
47Roach PJ, Francis RL, Emmett L, et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med 2018;59:82-88.
48Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208-1216.
49Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-425.
50Høilund-Carlsen PF, Hess S, Werner TJ, Alavi A. Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift! Eur J Nucl Med Mol Imaging 2018;45:893-897.
51Ceci F, Fanti S. PSMA PET/CT imaging in prostate cancer: why and when. Clin Transl Imaging 2019:377-379.
52Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019;46:2536-2544.
53Le JD, Tan N, Sholyar E, et al. Multifocality and prostate cancer detection by Multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 2015;67:569-576.
54Demirci E, Kabasakal L, Şahin OE, et al.  Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun 2019;40:86-91.
55Lopcia E, Lughezzanib G, Castelloa A, et al. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/ Computed Tomography in Primary Prostate Cancer Diagnosis.  Eur Urol Focus 2020;S2405-4569:30092-30094.
56Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-1418.
57Schmuck S, von Klot CA, Henkenberens C, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 2017;58:1962-1968.
58Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using 68Ga-HBEDCC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging 2018;45:602-612. 
59Schmidkonz C, Cordes M, Schmidt D, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:1862-1872.
60Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E. [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 2019;9:84. Published 2019 Aug 29. doi:10.1186/s13550-019-0554-1.
61Grubmüller B, Senn D, Kramer G, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019;46:1063-1072.
62Grubmüller B, Rasul S, Baltzer P, et al. Ressponse assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 2020;80:74-82.
63Plouznikoff N, Artigas C, Sideris S, et al.   Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med 2019;33:945-954.
64Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 2003;4:407-414.
65Wright Jr GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
66Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 2015;75:242-254.
67Velikya I, 68Ga-based radiopharmaceuticals: Production and  application relationship molecules 2015;20:12913-12943.
68Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-495.
69Hacıosmanoğlu T, Demir M, Toklu T, et al. Quality control and acceptance tests of positron emission tomography (PET) systems. Nucl Med Semin 2020;6:51-70.
70Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
71Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 2016;37:1169-1179.
72de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 2020;20:23. Published 2020 Mar 14.
73Alçin G, Gündoğan C, Mutlu İN, Çermik TF. 68Ga-prostate-specific membrane antigen-11 pet/ct ı ncidental finding of a vestibular schwannoma. Clin Nucl Med 2019;44:883-885.
74Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011;108:9578-9582.
75Kranzbühler B, Salemi S, Umbricht CA et al. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate 2018;78:758-765.
76Zukotynski KA, Valliant J, Bénard F, et al. Flare on serial prostate-specific membrane antigentargeted 18F-DCFPyL PET/CT examinations in castration resistant prostate cancer: first observations. Clin Nucl Med 2018;43:213-216.
77Aggarwal R, Wei X, Kim W, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 2018;1:78-82.
78Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018;59:469-478.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House